The Toxicogenomics project has been constructing a large-scale database of about 150 compounds exposed to rat (single dose, 3, 6, 9, 24 hrs and repeated dose for 3, 7, 14 28 days with 3 dose levels) and rat hepatocytes (2, 8, 24 hr with 3 concentrations) and data of transcriptome in liver using GeneChip, and the related toxicological measures are being accumulated. In the present study, the data of three ligands of peroxisome proliferator activated receptor α (PPARα), i.e., clofibrate, WY-14643 and gemfibrozil in our database were analyzed. Many of the β-oxidation-related genes were commonly induced in vivo and in vitro, whereas expression changes in genes related to cell proliferation, apoptosis, were detected in vivo (single and repeated dose) but not in vitro. Changes in those related to the immune response, coagulation and the stress response were also detectable exclusively in vivo. Using the genes mobilized in two or three PPARα agonists, hierarchical clustering was performed on 32 compounds stored in our database. In the profiling of an in vivo single dose, benzbromarone and aspirin were located in the same cluster of the three PPARα agonists. The clustering of in vitro data revealed that benzbromarone, three NSAIDs (aspirin, indomethacin and diclofenac sodium) and valproic acid belonged to the same cluster of PPARα agonists, supporting the reports that benzbromarone,valproic acid and some NSAIDs were reported to be PPARα agonists. Using the genes commonly up-regulated both in vivo and in vitro, principal component analysis was performed in 32 compounds, and principal component 1 was found to be the convenient parameter to extract PPARα agonist-like compounds from the database.
INTRODUCTION
The Toxicogenomics Project is a 5-year collaborative project conducted by the National Institute of Health Sciences (NIHS) and 17 pharmaceutical companies in Japan which started in 2002 (Urushidani and Nagao, 2005) . In April 2005, some rearrangements were made and now the project is conducted by NIHS, the National Institute of Biomedical Innovation, and 15 pharmaceutical companies. Its aim is to construct a large-scale toxicology database of transcriptome for prediction of toxicity of new chemical entities in the early stage of drug development. About 150 chemicals, mainly medicinal compounds, have been selected, and the following are examined for each. The in vivo test using rats consists of a single administration test (3, 6, 9 and 24 hr with 4 dose levels including vehicle control) as well as a repeated administration test (3, 7, 14 and 28 days with 4 dose levels including vehicle control) and the data of body weight, general symptoms, histopathological examination of liver and kidney, and blood biochemistry are obtained from each animal. The gene expression in liver (kidney in some cases) is comprehensively analyzed using Affymetrix GeneChip. An in vitro test using rat and human hepatocytes is also carried out to accomplish the bridging between the species. By the time the present study was performed, more than 100 chemicals covering wide medication categories had been finished or were ongoing, and the whole data set of 32 compounds had been stored in the database ready for analysis. We have started the analysis with three fibric acids in the database, i.e., clofibrate, WY-14643 and gemfibrozil (ligands of peroxisome proliferator-activated receptor α, PPARα). They have been extensively studied regarding their mechanism of toxicity, as we consider them excellent model cases for evaluating the quality of our database.
MATERIALS AND METHODS

Compounds
All compounds were of the highest grade obtainable from the suppliers listed in Table 1 .
In vivo studies
Male Sprague-Dawley rats were purchased from Charles River Japan Inc., (Kanagawa, Japan) at 5-weeks of age. After a 7-day quarantine and acclimatization period, the animals were divided into groups of 5 animals using a computerized stratified random grouping method based on body weight for each age. The animals were individually housed in stainless-steel cages on a 12 hr light/dark cycle. Each animal was allowed free access to water and pellet food (CRF-1, sterilized by radiation, Oriental Yeast Co., Japan). The test compounds were suspended in 0.5% methylcellulose solution or corn oil. Animals were orally administered daily at three dose levels for 1, 3, 7, 14 and 28 days. The highest dose level for each was determined in a 1-week dose-finding study (data not shown), and 1/3 and 1/10 of that were set as middle and low doses, respectively. The dose levels are given in Table 1 .
Blood samples were taken at 3, 6, 9, and 24 hr after single dosing and 24 hr after repeated dosing with a needle and a heparinized syringe from the abdominal artery of animals under ether anesthesia. Plasma biochemical assessments were conducted by using COBAS MIRA plus autoanalyzer (Roche Diagnostics, Basel, SZ). After collecting the blood, the animals were euthanized by exsanguination from the abdominal veins and arteries under ether anesthesia. Livers were collected from each animal and weighed, then a portion (about 30 mg) of each left lateral lobe was put into RNAlater ® (Ambion, Austin, TX, USA) for expression profiling. The remaining liver samples were fixed in 10% buffered formalin solution for routine histological processing. Paraffin sections were stained with hematoxylin and eosin for histopathological examination. The experimental protocols were reviewed and approved by the Ethics Review Committee for Animal Experimentation of the National Institute of Health Sciences.
In vitro studies
Hepatocytes were isolated from 6-week-old male Sprague-Dawley rats under sodium pentobarbital (120 mg/kg, ip) by a modified two-step collagenase perfusion method. The liver was perfused via the portal vein for 10 min with divalent cation-free EGTA (0.5 mM)-supplemented HEPES buffered Hank's balanced salt solution followed by a 10-min perfusion with HEPESbuffered normal Hank's balanced salt solution containing soybean trypsin inhibitor (Sigma, T-2011, 0 .05 g/ L) and collagenase (WAKO 034-10533, 0.5 g/L) at a flow rate of 10 -30 ml/min. Isolated cells were washed three times by 50 g for 1 min to obtain a parenchymal cell-enriched pellet. Hepatocytes were not used when their viability assessed by trypan blue exclusion was lower than 70%. The cells were seeded into collagencoated six-well plates (BD BioCoat ® Collagen I Cellware, BD Bioscience) at a density of 1×10 6 cells/well in 2 ml HMC Bulletkit medium (CAMBREX) supplemented with 10% fetal bovine serum. Following an attachment period of 3 hr, the medium was replaced and kept overnight before drug exposure at 37°C in an atmosphere of 5% CO 2 . The test compounds were added to the medium directly or as a 1,000× stock solution in dimethylsulfoxide. The highest concentration of each compound was determined in a pilot test based on cytotoxicity (ca. 20% release of lactate dehydrogenase) and 1/5 and 1/25 of that were set as middle and lowest concentrations (data not shown). After 2, 8 and 24 hr-exposure, the cells were dissolved with RLT buffer (Qiagen) and collected for expression profiling. GeneChip ® analysis was performed in a duplicated manner for each time and concentration point.
Expression profiling
The livers were homogenized using Mill Mixer Vol. 31 No. 5 (Qiagen) and zirconium beads. Total RNA was isolated from the liver homogenate or the hepatocyte lysate using RNeasy kit. Purity of the RNA was checked by gel electrophoresis, and the OD260/280 nm ratio was between 2.0-2.2. Microarray analysis was conducted on 3 out of 5 samples for each group by using GeneChip ® RAE230A probe arrays (Affymetrix, Santa Clara, CA, USA), containing 15923 probe sets. The procedure was conducted basically according to the manufacturer's instructions using Superscript Choice System (Invitrogen, Carlsbad, CA, USA) and T7-(dT)24-oligonucleotide primer (Affymetrix) for cDNA synthesis, cDNA Cleanup Module (Affymetrix) for purification, and BioArray High yield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY, USA) for synthesis of biotin-labeled cRNA. Twenty μg of the frag mented cRNA was hybridized to a RAE230A probe array for 18 hr at 45°C at 60 rpm, after which the array was washed and stained by streptavidin-phycoerythrin using Fluidics Station 400 (Affymetrix) and then scanned by Gene Array Scanner (Affymetrix). The data were analyzed by using GeneSpring ® version 6.1 (Silicon Genetics, Santa Clara, CA, USA). Expression data were normalized using the mean value (global normalization). Filtering of the data was performed by flags (present or marginal call) in at least half of the samples, as well as the fold change, over the concurrent control value.
Principal components analysis
To test whether profiling on in vivo effects of compounds can be estimated from in vitro transcriptome data, principal component analysis (PCA) on the data of three time points (24 hr after in vivo single dose, 29 day after in vivo repeated dose, and 24 hr after in vitro exposure) was independently conducted using the expression of 41 genes which changed to the same direction both in vitro and in vivo (single or repeated dose). The method of gene selection is described in the results section.
For calculation, we took the mean signals from three (in vivo) or two (in vitro) samples from each dose group and calculated the ratio for each respective control, and subsequently the values were transformed to log ratio to create a matrix. Each row corresponds to a different gene, and each column corresponds to a different condition including three different dose groups of 32 compounds. To compute the principal components, the eigenvalues and their corresponding eigenvectors were calculated from the correlation matrix of conditions. The calculations were done using the R version 2.2.0 (www.r-project.org) statistical environment.
RESULTS
Pathology
Toxicological changes observed in repeated administration of three peroxisome proliferators are summarized in Fig. 1 . All three chemicals showed a significant increase in the relative liver to body weight after 4 days or later of administration (Fig. 1A) . They also showed a significant decrease in triglyceride after the 4th day of administration, known to be directly related to their activity of PPARα agonist (Fig. 1B) . Signs of hepatotoxicity and an increase in ALT activity were observed in the 4th day of WY-14643-and the 29th day of gemfibrozil-treated groups ( Fig. 1-C) . In pathological examinations, granular degeneration of hepatocytes was noted in all compounds. Furthermore, an increase in hepatocyte proliferation was observed in WY-14643 and gemfibrozil. Treatment with WY-14643 also induced necrosis of hepatocyte and hypertrophy of the bile duct (data not shown).
Analysis of mRNA expression profile
Differentially expressed genes in liver treated with clofibrate, WY-14643 and gemfibrozil were extracted as follows. For in vivo study, genes with present call in at least 3 out of 6 samples for each experimental set (3 each from control and treated group) were selected and used for further analysis. In the case of the in vitro study, genes with present call in at least 2 out of 4 samples in each experimental set (2 each from control and treated) were selected. Genes showing at least a 1.5 fold increase (or 1/1.5 fold decrease) both in middle and high dose vs. control at p<0.05 by Student's t-test were extracted for each time point. In the case of in vitro study, the same procedure without use of t-test was employed. In the next step, the common genes selected in at least 2 out of three peroxisome proliferators for single, repeated, and in vitro experiments were extracted. The numbers of genes extracted as above were as follows: the up-regulated genes, 115/195/89 for in vivo-single/in vivo-repeated/ in vitro, respectively; and the down-regulated genes, 181/221/38, for in vivo-single/in vivo-repeated/ in vitro, respectively. The overlapping of these genes is depicted in a Venn diagram in Fig. 2 .
Comparing the extracted genes between the protocols, 71, 29, and 37 up-regulated genes were in common between the single and repeated administration, between single administration and in vitro, and between repeated administration and in vitro, respectively. For down-regulated genes, 44 genes were in common between single and repeated administration, whereas no common genes were present between in vivo and in vitro. These genes are listed in Table 2 (upregulated) and Table 3 (down-regulated).
Most of the genes categorized in β-oxidation and Vol. 31 No. 5 fatty acid and cholesterol synthesis, and the peroxisomal protein, were commonly changed both in vivo and in vitro. In general, genes related to lipid metabolism were commonly up-regulated in vivo and in vitro except that apolipoprotein A-IV, apolipoprotein M, and lipoprotein-binding protein were down-regulated only in vivo (mainly repeated dose). As for genes related to lipid metabolism other than that listed above, most of the up-regulated ones were common between in vivo and in vitro, whereas the down-regulated ones were only observed in vivo (single and repeated dose).
Of the genes related to carbohydrate metabolism, elevation of pyruvate dehydrogenase kinase 4 was observed both in vivo (single and repeated dose) and in vitro, whereas reduction of "pyruvate kinase liver and RBC" was observed only in vivo (mainly repeated dose) and others were increased in vivo (single and repeated dose).
The genes classified as cell proliferation were upor down-regulated only in vivo (single and repeated dose). Some genes, including cyclin D1, showed more marked changes in single dose than in repeated dose. The changes of genes categorized in apoptosis were only detectable in vivo and their changes were also more prominent in single dose than in repeated dose.
Obvious changes were noted in the genes related to "drug and xenobiotic metabolism" and most of them occurred exclusively in vivo (single and repeated dose). The only observable changes in growth factor-related genes were a reduction of the in vivo repeated dose. Changes in the expression of genes related to "cellular morphogenesis" as well as the "stress response" were mainly noted in vivo (single and repeated dose). Many other genes categorized to "transcription activation and repression", "transporter", "cell adhesion", "immune response", "blood coagulation", "regulation of blood . Values were obtained 24 hr after repeated administration of each drug for 3, 7, 14, and 28 days. Middle and high dose was 100 and 300 mg/kg for clofibrate, 30 and 100 mg/kg for WY-14643, and 100 and 300 mg/kg for gemfibrozil, respectively. For simplicity, data of the low dose was omitted. *Significantly different from control (p<0.05, Student's t-test, N=5).
pressure" were found to be down-regulated in vivo without any changes in vitro.
Hierarchical cluster analysis
Hierarchical clustering (complete linkage method, Euclidean distance) was performed in the 32 compounds stored in our database (the number at that stage of our analysis) using the data of gene expression in vivo or in vitro (24 hr after middle and high dose). The probe sets used for analysis of in vivo data were 36 (up-regulated) and 35 (down-regulated) which showed a more than 1.5 fold change with p<0.05 by Student's t-test both in middle and high dose of more than 2 compounds out of clofibrate, WY-14643 and gemfibrozil. The probe sets used for analysis of in vitro data were 49 (up-regulated) and 6 (down-regulated) which showed a more than 1.5 fold change with p<0.05 by Student's t-test both in the middle and the high doses of more than 2 out of the three compounds. In clusters of single-dose experiments, benzbromarone and aspirin were classified into the same cluster of the three peroxisome proliferators (Fig. 3) . In clusters of the in vitro experiments, benzbromarone, three non-steroidal antiinflammatory drugs (aspirin, indomethacin, and diclofenac sodium), valproic acid, and ANIT were classified into the same cluster of the three peroxisome proliferators (Fig. 4) .
PCA-based estimation of PPARα activity
As previously shown in Fig. 2 , no common down-regulated genes existed between in vivo and in vitro, whereas 41 up-regulated genes were found to be common genes (between in vivo and in vitro) by PPARα agonist treatment. We expected that these genes could be useful for prediction of in vivo effects from in vitro effects, so PCA analysis was conducted on the 32 compounds using these 41 genes.
A projection on the first two principal components for each condition, together with the contribution rate of the first three components, is shown in Fig. 5 . It was obvious from the figure that the first principal component score (PC1) with high contribution (about 60%) for all three experimental sets, was negatively correlated to the dose levels of these PPARα ligands. Therefore, we reasoned that this negative PC1 score could be used to estimate the PPARα activity in general. Fig. 6 shows the plotting of negative PC1 values from the 32 compounds examined in vivo and in vitro. In this figure, a clearer comparison of putative PPAR α activity between the compounds can be performed. All the PPARα agonists showed high scores both in vivo and in vitro. Benzbromarone, aspirin and valproic acid again showed high scores both in vivo and in vitro. It was also easy to pick up the compounds that showed high scores in vitro rather than in vivo, such as diclofenac and indomethacin. : The largest fold change among the single dose studies of CFB, WY and GFZ is shown. b) : The largest fold change among the repeated dose studies of CFB, WY and GFZ is shown. c) : The largest fold change among in vitro studies of CFB, WY and GFZ is shown. The columns are shaded when the corresponding probe sets appear in Fig. 2 . *: Probes which were used in the PCA analysis. 
DISCUSSION
In the present study, analysis of gene expression in rat liver was done with three peroxisome proliferators, clofibrate, WY-14643 and gemfibrozil, stored in our database. The changes of gene expression by these compounds observed in vivo (single and repeated) were largely in accordance with the report by Kramer et al. (2003) , in which the effect of clofibrate on the gene expression profile in rat liver was analyzed. Among the genes whose expression was affected, a large number of genes were overlapped between in vivo and in vitro, both in up-and down-regulated ones. Between in vivo and in vitro experiments, however, there were many common genes in up-regulated ones but none in down-regulated ones.
A large number of genes related to b-oxidation were up-regulated by a single dose, and similar changes were also noted for in vitro experiments. The genes that possess PPRE sequence in their promoter regions, e.g., acyl-CoA oxidase (Tugwood et al.,1992) , carnitine palmitoyl transferase I (Brandt et al., 1998) , carnitine palmitoyl transferase II (Barrero et al., 2003) and fatty acid desaturase 2 (Tang et al., 2003) were found to be up-regulated both in vivo and in vitro. An exception was that malic enzyme (Castelein et al., 1994) , whose promoter region contains PPRE, was induced in vivo but not in vitro. On the other hand, there were many genes whose promoter regions had no PPRE sequence showing common induction for in vivo and in vitro. For example, CD36, a fatty acid transporter, and CYP4A14, involved in fatty acid hydroxylation, were up-regulated both in vivo and in vitro, but there has been no report that their promoter regions contain functional PPRE. Apart from their mechanism, the genes that show common changes in vivo and in vitro (as listed by the present study) are considered to be useful to assess pharmacological and toxicological effects in vivo from in vitro experiments. This will be discussed later.
There were also data suggesting the limitations of in vitro experiments. Among the genes modulated by administration of fibrates in vivo, those related to the functions of proliferation, apoptosis, immune response, transcription activation and repression, transporter, cell adhesion, blood coagulation and regulation of blood pressure, did not show any changes in vitro. It is well known that peroxisome proliferators are nongenotoxic carcinogens for rodents and their most convincing mechanism is presently considered to be the activation of proliferation in addition to attenuation of apoptosis (Michalik et al., 2004; Boitier et al., 2003) . In the present study, many of the genes related to proliferation and apoptosis were mobilized by fibrates in vivo but not at all in vitro. There have been many reports describing the fact that stimulation of proliferation by peroxisome proliferators requires Kupffer cell or TNFα produced by the cell. Rose et al. (1997) 
The smallest ratio to control value observed in single-dose studies of CFB, WY and GFZ is shown. Negative figure means the reciprocal number of ratio; e.g., −3.0 means that one of the drugs reduced the gene expression to 1/3 of corresponding control. b) : The smallest ratio to control value observed in repeated dose studies of CFB, WY and GFZ is shown. c) : The smallest ratio to control value observed in vitro studies of CFB, WY and GFZ is shown. The columns are shaded when the corresponding probe sets appear in Fig. 2. reported that acceleration of proliferation in rat hepatocytes by WY-14643 was attenuated by the reduction of TNFα via inactivation of Kupffer cells. It was also reported that WY-14643 failed to cause cell proliferation in hepatic parenchymal cells cultured under the condition where non-parenchymal cells had been eliminated, and that its proliferative effect was recovered when Kupffer cells were added to the culture (Parzefall et al., 2001) . As for the attenuation of apoptosis, it was reported that a high concentration of TNFα inhibited spontaneous TGFβ1-induced apoptosis in primary cultured hepatocytes (Rolfe et al., 1997) . These reports Fig. 3 . A heat map view of the gene expression profile for the 32 compounds in vivo. Hierarchical clustering analysis of the compounds (middle and high dose, 24 hr after a single dose) was conducted using the genes that were increased (1398296_at, 1398249_at, 1390851_at, 1389551_at, 1389253_at, 1388924_at, 1388891_at, 1388756_at, 1388223_at, 1387977_at, 1387783_a_at, 1387740_at, 1387636_a_at, 1387183_at, 1387022_at, 1386927_at, 1386885_at, 1386880_at, 1379361_at, 1375845_at, 1374475_at, 1373784_at, 1373564_at, 1372134_at, 1371976_at, 1371379_at, 1370870_at, 1370818_at, 1370397_at, 1370067_at, 1368934_at, 1368283_at, 1367937_at, 1367777_at, 1367694_at, 1367659_s_at) or decreased (1398362_at, 1391485_at, 1390172_at, 1390165_at, 1390115_at, 1389218_at, 1388742_at, 1388459_at, 1387913_at, 1382944_at, 1377375_at, 1376746_at, 1376709_at, 1376593_at, 1376140_at, 1375205_at, 1374493_at, 1374320_at, 1374266_at, 1373797_at, 1372308_at, 1371368_at, 1371202_a_at, 1370043_at, 1369973_at, 1369868_at, 1368698_at, 1368642_at, 1368497_at, 1368428_at, 1368304_at, 1368036_at, 1367905_at, 1367602_at, 1367601_at ) 24 hr after a single dose (complete linkage method, Euclidean distance). A cluster consisting of 3 fibrates (CFB, WY, GFZ), benzbromarone (BBr) and aspirin (ASA) was identified on the left side.
suggest that a Kupffer cell secreting TNFα, IL-1, IL-2 and IL-6 (Decker, 1990) plays an important role in hepatocyte proliferation stimulated by peroxisome proliferators. Our present results that the expression changes of genes related to proliferation or apoptosis were rarely observed for the in vitro system could be due to the fact that the numbers of non-parenchymal cells (including Kupffer cells) in the culture were much less than that for in vivo liver. Our present results also support the aforementioned concept that the Kupffer cell (or its production of TNFα) is essential for the increase of proliferation and attenuation of apoptosis caused by peroxisome proliferators.
Many genes related to cellular morphogenesis, including extracellular matrix (ECM), were down-regulated exclusively in vivo. Ogata et al. (2002 Ogata et al. ( , 2004 reported that the increase in mRNA of collagen type I and type III in pressure-overloaded rat heart was reduced by the administration of fenofibrate and that the proliferation of cardiac fibroblast induced by endothelin-1 was inhibited by fenofibrate. It was also reported that ETYA, a PPARα agonist, reduced the mRNA contents of elastin, tropoelastin and α-smooth muscle actin in neonatal rat lung fibroblast ( McGowan   Fig. 4 . A heat map view of the gene expression profile for the 32 compounds in vitro. Hierarchical clustering analysis of the compounds (middle & high concentrations, 24 hr of exposure) was conducted using the genes that were increased (1398310_at, 1394194_x_at, 1390383_at, 1390370_at, 1389253_at, 1388924_at, 1388756_at, 1388644_at, 1388211_s_at, 1388108_at, 1387783_a_at, 1387740_at, 1386946_at, 1386927_at, 1386901_at, 1386885_at, 1386880_at, 1383205_at, 1379361_at, 1377037_at, 1376076_at, 1374556_at, 1374478_at, 1374265_at, 1370818_at, 1370436_at, 1370397_at, 1370355_at, 1370313_at, 1370310_at, 1370237_at, 1369150_at, 1369111_at, 1368934_at, 1368797_at, 1368669_at, 1368435_at, 1368283_at, 1368150_at, 1368034_at, 1368021_at, 1367950_at, 1367897_at, 1367836_at, 1367777_at, 1367742_at, 1367689_a_at, 1367672_at, 1367659_s_at) or decreased (1387246_at, 1375791_at, 1373261_at, 1369093_at, 1368798_at, 1368342_at) The left two panels show the in vivo studies, i.e., 24 hr after single dose and 24 hr after the last dose of the 28-day repeated dose, and the right panel shows the in vitro study, 24 hr exposure. The x-axis for each shows the negative value of PC1, as in Fig. 5 , and the y-axis shows the compounds aligned alphabetically. The abbreviations of the compounds are found in , 1997 ). It appears that peroxisome proliferators also act on non-parenchymal cells other than Kupffer cells, and that they reduce the production of ECM in fibroblasts. Stellate cell, a hepatic non-parenchymal cell, possesses both of the characteristics of lipocyte and fibroblast, and its ability to produce ECM was found to be increased in liver fibrosis (Tanaka et al., 1991) . It is possible that production of ECM in stellate cells could be stimulated by peroxisome proliferators. Based on these ideas, it would be reasonable to conclude that the reduction of expression of genes related to ECM and cytoskeletons by peroxisome proliferators observed in vivo were not reproduced in the in vitro system, considering that these changes were a reflection of those occurring in non-parenchymal cells in liver. In the present study, relative liver weight was increased by a factor of two in peroxisome proliferators. The expression changes in genes classified to cell adhesion and cellular morphogenesis should have been associated with this obvious hypertrophy of the liver. In the present study, down-regulation of genes classified to the immune response and coagulation was also in vivo-specific. PPARα is known to function as an inhibitory factor for inflammation, and PPARα agonists were reported to inhibit the expression of mRNA of fibrinogen, an acute phase protein (Kockx et al., 1999; Corton et al., 1998) , and induction of fibrinogen gene by IL-6 (Gervois et al., 2001) . Moreover, it was also reported that WY-14643 inhibits induction of IL-6 and cyclooxygenase-2 by IL-1 in human aortic smooth muscle cells through inhibition of the translocation of NF-κB from the cytosol to the nucleus. It is thus expected that inhibition of the inflammatory response by PPARα agonists not only affects the hepatic parenchymal cell (producing acute phase proteins) but also affects the mechanism relating to non-parenchymal cells (including Kupffer cell) that releases inflammatory cytokines. It would be reasonable to conclude that the reason down-regulation of genes classified to the immune response and coagulation was observed in vivo but not in vitro was again due to the involvement of non-parenchymal cells. However, it might be due simply to the fact that the basal level of the mRNAs of these genes was down-regulated during our culture condition, since there was a report that PPARα agonist could inhibit the expression of fibrinogen mRNA by IL-6, using human hepatocyte culture (Gervois et al., 2001) .
As discussed above, the profiling of in vivo data represents gene expression in multiple cellular populations, whereas the profiling of in vitro data is focused on gene expression of hepatic parenchymal cells. The advantage of the in vitro system is that the direct effects of chemicals on hepatic parenchymal cells can be assessed, and in certain cases, the sensitivity and specificity of the test can be improved by eliminating noise due to gene expression of non-parenchymal cells. On the other hand, the in vitro system has an apparent disadvantage when indirect toxicity to parenchymal cells via non-parenchymal cells is involved or direct toxicity to non-parenchymal cells is involved.
In hierarchical clustering analysis of the in vivo data stored in our database, benzbromarone and aspirin were classified into the same cluster of the three peroxisome proliferators. It has been long known that benzbromarone is a PPARα ligand (Bichet et al., 1990) . As for aspirin, some NSAIDs including indomethacin, ibuprofen and fenoprofen, were reported to activate PPARα (Lehmann et al., 1997) , suggesting that aspirin belongs to PPARα agonists as well. In the hierarchical cl us te ri ng o f th e in vi tro da ta, t wo NSA IDs (indomethacin and diclofenac) and valproic acid were additionally located to the same cluster that included the three fibrates, and benzbromarone and aspirin. It has been reported that valproic acid induced the increase of liver weight and the activation of β-oxidation in rodents, suggesting that the drug has some PPARα agonist-like activity (Horie and Suga, 1985) . Although the middle dose of ANIT belonged to the same cluster, its high dose showed a quite different profile. There is no report suggesting a relationship between ANIT and PPARα so far. One possibility is that ANIT is a potential PPARα agonist, and inconsistent results at high concentrations showed that cytotoxicity overwhelmed the inducing effects. At the middle dose of ANIT, various genes related to lipid metabolism (including β-oxidation), e.g., Acaa1, Acaa2, Cpt1a, C pt1b, P dk4, Ehhadh, H mgcs 2, M te1, Cyp4a14, Cyp4b1, Cyp8b1, and Angptl4 were up-regulated more than twice of control in vitro. It would be interesting to examine the direct effect of ANIT on PPARα. It should be considered that any expression changes in β-oxidation-related genes do not necessarily indicate the direct involvement of PPARα.
The reason why the in vitro system was more sensitive than that of in vivo for detecting PPARα agonistlike activity is the high concentration of the drugs in vitro. In the standard protocol in our project, the maximal dose of the drugs in vivo is set to the level which the animals can tolerate for 28 days of repeated administration, while that for in vitro is independently determined according to the direct cytotoxicity of the cul-tured hepatocytes. Therefore, in the case of chemicals causing severe toxicity to organs other than the liver, the practical concentration around the hepatocyte becomes much lower in vivo than in vitro. Since the main lethal cause in the case of NSAIDs is intestinal perforation, the doses employed were relatively low compared with that needed to elicit PPARα activation in vivo, and actually, a reduction of plasma lipid was barely observed. The PPARα activity of aspirin could possibly have been detected because its ulcerogenicity to intestine is much lower than that of the other NSAIDs.
One of the aims of the present project is the prediction of in vivo effects from in vitro experiments that have the advantages of saving chemicals, cost, and time. In the case of PPARα agonists, we could not find any common genes in down-regulated ones between in vivo and in vitro. On the other hand, 41 genes up-regulated in vitro were also up-regulated in vivo. We considered these as useful markers to predict PPARα activity in vivo from in vitro, and applied them to PCA. As shown in Fig. 5 , PC1 appeared to have a PPARα agonist-like attribute, and 32 chemicals were aligned by this parameter in Fig. 6 . This presentation conveniently identifies potential PPARα agonists both in vivo and in vitro. We are now incorporating this computing module into our toxicity prediction system and it will be useful in identifying other properties when appropriate marker genes are extracted.
In conclusion, our database efficiently works to classify a certain category of drugs (PPARα agonist in the present case) based on gene expression profiling. For these data, the gene expression profile in vitro is useful and sensitive to the direct toxicity of the chemicals in hepatic parenchymal cells, whereas indirect toxicities mediated by other cells or secondary toxicity due to pathophysiological changes such as blood pressure or inflammation in other organs might be overlooked. In order to predict in vivo effects from the in vitro system, it is important to identify genes commonly mobilized in vivo and in vitro. The scoring system (using the principal component that largely contributes the target effect) in the present study appeared to be quite useful and convenient to identify compounds with target activity among the ones stored in our database.
